Clinical Trial Update: Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase 1/2 trial evaluating Ecopipam, a D1-specific antagonist, for Restless Legs Syndrome with augmentation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Ecopipam (Ecopipam)

Snippet

Sponsor: William Ondo, MD | Conditions: Restless Legs Syndrome, Augmentation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-04-27